About +
Our Story
Meet the Team
Inhaled Interferon β +
Our Programmes
Publications
Investors +
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
News +
Press Releases & Media
TR-1/Options Press Releases
Careers
Contact
About
Inhaled Interferon β
Investors
News
Careers
Contact
Back
Our Story
Meet the Team
Back
Our Programmes
Publications
Back
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
Back
Press Releases & Media
TR-1/Options Press Releases
Interferon Beta
Relevant Publications
Safety and efficacy of inhaled nebulized interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomized, double-blind, placebo-controlled, phase 2 trial
Treatment of SARS with human interferons
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Antiviral activities of type I interferons to SARS-CoV-2 infection
Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Immunology of COVID-19: Current State of the Science
The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial
Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19